Singapore – A new multicenter, retrospective analysis of South Korean patients highlighted that the oral targeted ...
Merck and Pfizer Inc. announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combinatio...
Vyera Pharmaceuticals, LLC has announced that it plans to initiate a Phase 1 single ascending dose (SAD) study of ...
Singapore - BC Platforms, a world leader in secure genomic data management and analytics, announces an agreement with Na...
Singapore - Philip Morris International (PMI), has conducted an in vitro study using epithelial cells taken from the mou...
Adagene, an innovative antibody engineering and discovery company based in Suzhou, China as well as San Francisco, Calif...
Daiichi Sankyo Company, Limited announced that it has entered into a clinical trial collaboration agreement with Merck K...
Eisai Co., Ltd. and Biogen Inc. announced that Eisai presented the latest data from the Phase II clinical study (Study 2...
Reistone Biopharma Company Limited, a clinical stage biopharmaceutical company headquartered in Shanghai has announced&...
Singapore – ASLAN Pharmaceuticals, a clinical-stage biopharmaceutical company targeting cancers that are both...
apceth Biopharma GmbH, a company with the mission of improving patients’ lives with next generation cell therapies...
Singapore - Medivir AB announced plans to reduce activities not critical to its development pipeline of drug candidates ...
Alphamab Oncology has announced that its proprietary humanized PD-L1 - CTLA-4 bispecific antibody program, the first of ...
Yisheng Biopharma Co., Ltd., a biopharmaceutical company focusing on research, development, manufacturing, sales and mar...
Eisai Co., Ltd. has announced that its U.S. subsidiary Eisai Inc. received approval from the U.S. Food and Drug Administ...
Atox Bio, a clinical stage biotechnology company developing novel therapies for critically ill patients has announced th...
Immutep Limited has announced that it has entered into a clinical trial collaboration and supply agreement with Merck KG...
David T. Novotny was recently named Chief Strategy Officer (CSO) of Proxima Clinical Research, Inc., a leader in clinica...
